Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial
- 1Department of Medicine, Jung-Stilling Hospital, Siegen, Germany
- 2Division of Gastroenterology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
- 3Rheumaklinik Wiesbaden II, Wiesbaden, Germany
- 4Gesundheitszentrum Süd, Vienna, Austria
- 5Department of Medicine, Hospital Nordwest, Frankfurt, Germany
- 6Institute of Pathology, Klinikum Bayreuth, Bayreuth, Germany
- 7Division of Gastroenterology, Department of Internal Medicine, Triemli Hospital, Zurich, Switzerland
- Correspondence to:
Professor H R Koelz, Division of Gastroenterology, Department of Internal Medicine, Triemli Hospital, Birmensdorferstrasse 497, CH-8063 Zurich, Switzerland;
- Accepted 9 January 2002
Background: There is much controversy as to whether or not treatment of Helicobacter pylori reduces the occurrence of peptic ulcers during therapy with a non-steroidal anti-inflammatory drug (NSAID).
Aim: To assess the efficacy of triple therapy or omeprazole on the occurrence of diclofenac associated ulcers in H pylori positive patients.
Methods: This was a randomised, double blind, placebo controlled, multicentre trial in H pylori positive patients requiring NSAID therapy who had no past or current peptic ulcer. They received diclofenac 50 mg twice daily for five weeks in combination with one of the four randomly assigned treatments: anti-H pylori treatment for one week (omeprazole 20 mg+clarithromycin 500 mg+amoxicillin 1 g, all twice daily) followed by placebo for four weeks (OAC-P); anti-H pylori treatment for one week followed by antisecretory treatment with omeprazole 20 mg once daily for four weeks (OAC-O); omeprazole 20 mg once daily for five weeks (O-O); or placebo for five weeks (P-P). Patients were endoscoped before and after treatment.
Results: Data from 660 patients were included in an intention to treat analysis. The occurrence of peptic ulcers in the four treatment groups during the study period was: 1.2% for OAC-P, 1.2% for OAC-O, 0% for O-O, and 5.8% for P-P (p<0.05 between placebo and all active treatment groups). Patients who received active treatment developed therapy requiring dyspeptic symptoms less frequently than those who received placebo (p<0.05 between placebo and all active treatment groups).
Conclusions: In H pylori infected patients, all three active therapies reduced the occurrence of NSAID associated peptic ulcer and dyspeptic symptoms requiring therapy.
- NSAID, non-steroidal anti-inflammatory drug
- COX-2, cyclooxygenase 2
- RR, relative risk
- OAC-P, omeprazole+amoxicillin+clarithromycin, followed by placebo
- OAC-O, omeprazole+amoxicillin+clarithromycin, followed by omeprazole
- O-O, omeprazole followed by omeprazole
- P-P, placebo followed by placebo
- PPI, proton pump inhibitor